Real-time telomerase activity measurements for detection of cancer

Expert Review of Molecular Diagnostics

Volumn 5, Issue 5, 2005, Pages 745-753

  Jakupciak, John P ^a  

^a NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY   (United States)

Author keywords

Biomarker; Diagnostics; Real time TRAP; Reference material; Telomerase

Indexed keywords

TELOMERASE; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; ENZYME ACTIVITY; FOLLOW UP; HUMAN; QUALITY OF LIFE; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; TELOMERIC REPEAT AMPLIFICATION PROTOCOL;

HUMANS; NEOPLASMS; POLYMERASE CHAIN REACTION; TELOMERASE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 25144433789     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.5.5.745     Document Type: Review

References (80)

1. Futreal PA, Coin L, Marshall M et al. A census of human cancer genes. Nature Rev. Cancer 4, 177-183 (2004).
2. Preston RJ. Mechanistic data and cancer risk assessment. Environ. Mol. Mut. 45, 310-319 (2005). Comprehensive overview of approaches to use biomarker data for cancer risk assessment.
3. Leaf C. The war on cancer. Fortune Magazine March 22, 77-95 (2004). Perspective on the clinical track record of cancer drugs.
4. Frist WH. Healthcare in the 21st century. N. Engl. J. Med. 352, 267-272 (2005).
5. Hirsch FR, Franklin WA, Gazdar AF et al. Early detection of lung cancer. Clin. Cancer Res. 7, 5-22 (2001).
6. Shay JW, Gazdar AF. Telomerase in the early detection of cancer. J. Clin. Pathol. 50, 106-109 (1997).
7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100, 57-70 (2000).
8. Poremba C, Heine B, Diallo R et al. Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J. Pathol. 198, 181-189 (2002).
9. Dong CK, Masutomi K, Hahn WC. Telomerase: regulation, function and transformation. Crit. Rev. Oncol. Hematol. 54, 85-93 (2005).
10. Yoshida K, Sugino T, Goodison S et al. Detection of telomerase activity in exfoliated cancer cells in colonic luminal washings and its related clinical implications. Br. J. Cancer 75, 548-553 (1997).
11. Yoshida K, Sugino T, Tahara H et al. Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer 79, 362-369 (1997).
12. Sidransky D. Emerging molecular markers of cancer. Nature Rev. Cancer 2, 210-219 (2002). Describes DNA-based markers, RNA-based approaches and protein-based assays for early detection of cancer.
13. Moyzis RK, Buckingham JM, Cram LS et al. A highly conserved repetitive DNA sequence present at the telomeres of human chromosomes. Proc. Natl Acad. Sci. USA 85, 6662-6626 (1988).
14. Smogorzewska, A, de Lange T. Regulation of telomerase by telomeric proteins. Ann. Rev. Biochem. 73, 177-208 (2004).
15. Harley CB, Futcher AB, Greider CW. Telomeres shorten during aging of human fibroblasts. Nature 345, 458-460 (1990).
16. Muller HJ. The remaking of chromosomes. Collecting Net. 8, 182-198 (1938).
17. McClintock B. The stability of broken ends of chromosomes. Zea mays. Genetics 26, 234-282 (1941).
18. Blackburn E, Bhattacharyya A, Gilley D et al. The telomere and telomerase: how do they interact? Ciba Found. Symp. 211, 2-13 (1997).
19. Greider CW, Blackburn EH. A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature 337, 331-337 (1989). Concludes that telomerase uses an essential RNA template.
20. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur. J. Cancer 33, 787-791 (1997).
21. Yahata N, Ohyashiki K, Ohyashiki JH et al. Telomerase activity in lung cancer cells obtained from bronchial washings. J. Natl Cancer Inst. 90, 684-690 (1998).
22. Kim NW, Piatyszek MA, Prowse KR et al. Specific association of human telomerase activity with immortal cells and cancer. Science 266, 2011-2015 (1994). Developed the telomeric repeat amplification protocol (TRAP), a PCR-based method for the assessment of telomerase activity, which allows for the use of very small amounts of tissue.
23. Piatyszek, MA, Kim NW, Weinrich SL et al. Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol. Methods Cell Sci. 17, 1-15 (1995).
24. Hess JL, Highsmith WE. Telomerase detection in body fluids. Clin. Chem. 48, 18-24 (2002). Reviews the sensitivity and specificity of TRAP assays to detect telomerase activity present in samples isolated from bronchial lavage, oral rinses and urine.
25. Meeker AK, Coffey DS. Telomerase, a promising marker of biological immortality of germ, stem, and cancer cells. Biochemistry 62, 1323-1331 (1997). Articulate review of issues associated with reported measurements of telomerase activity from 21 different cancer tissues, and benign and normal controls.
26. Hiyama E, Hiyama K. Clinical utility of telomerase in cancer. Oncogens 21, 643-649 (2002).
27. Hiyama K, Hirai Y, Koizumi S et al. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J. Immunol. 155, 3711-3715 (1995).
28. Ramirez RD, Wright WE, Shay JW et al. Telomerase activity concentrates in the mitotically active segments of human hair follicles. J. Invest. Dermatol. 108, 113-117 (1997).
29. Hiyama E, Hiyama K, Tatsumoto N et al. Telomerase activity in human intestine. Int. J. Oncol. 9, 453-458 (1996).
30. Kyo S, Nakamura M, Kiyono T et al. Successful immortalization of endometrial glandular cells with normal structural and functional characteristics. Am. J. Pathol. 163, 2259-2269 (2003).
31. Broccoli D, Young JW, de Lange T. Telomerase activity in normal and malignant hemotopoietic cells. Proc. Natl Acad. Sci. USA 92, 9082-9086 (1995). Definitive paper that proved human telomerase is not restricted to immortal cells and that its expression is widespread.
32. Smith LL, Coller HA, Roberts JM. Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nature Cell Bio. 5, 474-479 (2003).
33. Shay JW. Meeting report: the role of telomeres and telomerase in cancer. Cancer Res. 65, 3513-3517 (2005).
34. Yamamoto Y, Hirakawa E. Telomerase activity and hTERT mRNA expression in body fluids. Diagn. Cytopathol. 32, 167-170 (2005).
35. Braunschweig R, Guilleret I, Delacretaz F et al. Pitfalls in TRAP assay in routine detection of malignancy in effusions. Diagn. Cytopathol. 25, 225-230 (2001).
36. Braunschweig R, Yan P, Guilleret I et al. Detection of malignant effusions: comparison of a telomerase assay and cytologic examination. Diagn. Cytopathol. 24, 174-180 (2001).
37. Holman JW, Mifflin TE, Felder RA et al. Evaluation of an automated preanalytical robotic workstation at two academic health centers. Clin. Chem. 48, 540-548 (2002).
38. Maesawa C, Inaba T, Sato H et al. A rapid biosensor chip assay for measuring of telomerase activity using surface plasmon resonance. Nucl. Acids Res. 31, e4, 1-6 (2003). Methodical paper describing an alternative assay to TRAP that measures telomeric repeat elongation.
39. Jakupciak JP, Wang W, Barker PE et al. Validation of telomerase activity for cancer early detection: TRAP/PCR-CE and hTERT mRNA quantification assay for high-throughput screening of tumor cells. J. Mol. Diagn. 6, 157-165 (2004).
40. Elmore LW, Forsythe HL, Ferreira-Gonzalez A et al. Real-time quantitative analysis of telomerase activity in breast tumor specimens using a highly specific and sensitive fluorescent based assay. Diagn. Mol. PathoL 11, 177-185 (2002). First demonstration of real-time TRAP measurements using molecular beacon probes.
41. O'Connell CD, Tully LA, Devaney JM et al. Renewable standard reference material for the detection of TP53 mutations. Mol. Diagn. 7, 85-97 (2003).
42. O'Connell CD, Jakupciak JP. NIST reference materials for medical testing. In: Encyclopedia of Medical Genomics and Proteomics. Fuchs J, Podda M (Eds), Marcel Dekker Inc., NY, USA, 929-933 (2005).
43. Siracusano S, Niccolini B, Knez R et al. The simultaneous use of telomerase cytokeratin 20 and CD4 for bladder cancer detection in urine. Eur. Urology 47, 327-333 (2005).
44. Hess JL, Atha DH, Xu JF et al. Telomerase activity measurement in magnetically captured epithelial cells: comparison of slab-gel and capillary electrophoresis. Electrophoresis 25, 1852-1859 (2004). First TRAP measurements of circulating tumor cells, isolated from human blood for the early detection of lung cancer.
45. Jakupciak JP, Markowitz M, Ally D et al. Mitochondrial DNA as a cancer biomarker. J. Mol. Diagnostics 7, 258-267 (2005). First demonstration of the use of mitochondrial gene chips for the early detection of cancer-associated mutations in lung cancer.
46. Veenstra TD, Conrads TP, Hood BL et al. Biomarkers: mining the biofluid proteome. Mol. Cell. Proteomics 4, 409-418 (2005).
47. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351, 781-791 (2004). Demonstrates the feasibility of using circulating tumor cells from breast cancer patients to predict treatment efficacy and overall survival.
48. Srivastava S, Kramer BS. Early detection cancer research network. Lab. Invest. 80, 1147-1148 (2000). Describes the National Cancer Institute program to evaluate promising biomarkers for early detection of cancer.
49. Wagner PD, Maruvada P, Srivastava S. Molecular diagnostics: a new frontier in cancer prevention. Expert. Rev. Mol. Diagn. 4, 503-511 (2004).
50. Barker PE. Cancer biomarker validation: standards and process: roles for the National Institute of Standards and Technology (NIST). Ann. NY Acad. Sci. 983, 142-150 (2003).
51. Pepe MS, Etzioni R, Feng Z et al. Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst. 93, 1054-1061 (2001). Comprehensive overview that discusses various aspects of biomarker development to guide molecular screening.
52. Jakupciak JP, O'Connell CD. Standards and standardization of molecular diagnostics. In: Molecular Diagnostics for the Clinical Laboratorian. Coleman WB, Tsongalis GJ (Eds), Humana Press, Inc., NJ, USA, 243-246 (2005).
53. Ehrlich CD, Rasberry SD. Metrological timelines in traceability. J. Res. Natl. Inst. Std. Tech. 103, 93-105 (1998). National Institute of Standards and Technology policy on traceability.
54. Jakupciak JP, Barker PE, Wang W, Srivastava S, Atha DH. Preparation and characterization of candidate reference materials for telomerase assays. Clin. Chem. 51(8), 1443-1450 (2005).
55. Shankley N. Goal-driven drug discovery; getting the chemistry right. Nature Rev. Drug Discov. 1, 559-559 (2002).
56. Tahara H, Yasui W, Tahara E et al. Immunohistochemical detection of human telomerase catalytic component, hTERT in human colorectal tumor and non-tumor tissue sections. Oncogene 18, 1561-1567 (1999).
57. Hiyama E, Hiyama K, Yokoyama T et al. Immunohistochemical detection of telomerase hTERT protein in huam cancer tissues and a subset of cells in normal tissues Neoplasia 3, 17-26 (2001).
58. Yi X, Shay JW, Wright WE. Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. Nucleic Acids Res. 29, 4818-4825 (2001).
59. Wei R, Younes M. Immunohistochemical detection of telomerase reverse transcriptase in colorectal adenocarcinoma and benign colonic mucosa. Hum. Pathol. 33, 693-696 (2002).
60. Kyo S, Masutomi K, Maida Y et al. Significance of immunological detection of human telomerase reverse transcriptase, reevaluation of expression and localization of human telomerase reverse transcriptase. Am. J. Pathol. 163, 859-867 (2003).
61. Yan P, Benhattar J, Seelentag W et al. Immunohistochemical localization of hTERT protein in human tissues. Histochem. Cell Biol. 121, 391-397 (2004).
62. Leung DT-M, Ma C-H, Niu H et al Nuclear telomerase is less accessible to antibody probing than known nuclear antigens; retrieval with new immunostaining buffer. Histochem. Cell Biol 123, 105-112 (2004).
63. Hou M, Xu D, Bjorkholm M et al. Real-time quantitative telomeric repeat amplification protocol assay from the detection of telomerase activity. Clin. Chem. 47, 519-524 (2001).
64. Wege H, Chui MS, Le HT et al. SYBR green realtime telomeric repeat amplification protocol for the rapid quantification of telomerase activity. Nucl. Acids Res. 31, e3, 1-7 (2003).
65. Etzioni R, Urban N, Ramsey S et al. The case for early detection. Nature Rev. Cancer 3, 1-10 (2003).
66. Yu HP, Xu SQ, Lu WH et al. Telomerase activity and expression of telomerase genes in squamous dysplasia and squamous cell carcinoma of the esophagus. J. Surg. Oncol. 86, 99-104 (2004).
67. Zuo LF, Lin PZ, Qi FY et al. Flow cytometric analysis of DNA, telomerase content and multi-gene expression in esophageal epithelial dysplasia. World J. Gastroenterol. 9, 2409-2412 (2003).
68. Srivastava S. Cancer biomarkers: an emerging means of detecting, diagnosing, and treating cancer. Dis. Markers 21, 1-2 (2005).
69. Zhang W, Laborde PM, Coombes KR et al. Cancer genomics: promises and complexities. Clin. Cancer Rev. 7, 2159-2167 (2001).
70. Cristofanilli M, Hayes DF, Budd GT et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncology 23, 1420-1430 (2005).
71. Wemur JG, Davidson N. Kinetics of renaturation of DNA. J. Mol. Biol. 31, 349-370 (1968).
72. Wisman GB, Jong SD, Meersma GJ et al. Telomerase in preneoplastic cervical disease. Hum. Pathol. 31, 1304-1312 (2003).
73. Dikmen E, Kara M, Dikmen G et al. Detection of telomerase activity in bronchial lavage as an adjunct to cytological diagnosis in lung cancer. Eur. J. Cardiothorac. Surg. 23, 194-199 (2003).
74. Li SQ, Sheng ZM, Baili Y et al. Detection of hTERT mRNA in colonic brush specimens as an adjunct to cytopathologic diagnosis of colonic adenocarcinoma. Acta Cytol. 46, 1069-1074 (2002).
75. Heine B, Hummel M, Heicappell R et al. Non-radioactive measurement of telomerase activity in human bladder cancer, bladder washing and in urine. J. Pathol. 184, 71-76 (1998).
76. Califano J, Ahrendt SA, Meininger G et al. Detection of telomerase activity in oral rinses from head and neck squamous cell carcinoma patients. Cancer Res. 56, 5720-5722 (1996).
77. Yamamoto Y, Hirakawa E. Telomerase activity and HTERT mRNA expression in body fluids. Diagn. Cytopathol. 32, 167-170 (2005).
78. Counter CM, Gupta J, Harley CB et al. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 85, 2315-2320(1995).
79. Boushie A. Cancer trials get set for biomarkers. Nature Biotech. 22, 6-7 (2004).
80. Anderson NL, Andersen NG. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 1, 845-867 (2002).